Halozyme Therapeutics, Inc. (HALO)
| Market Cap | 5.75B |
| Revenue (ttm) | 471.57M |
| Net Income (ttm) | 434.92M |
| Shares Out | 137.95M |
| EPS (ttm) | 2.74 |
| PE Ratio | 15.22 |
| Forward PE | 17.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,320,908 |
| Open | 40.79 |
| Previous Close | 40.42 |
| Day's Range | 40.48 - 42.35 |
| 52-Week Range | 31.36 - 46.62 |
| Beta | 1.32 |
| Analysts | Buy |
| Price Target | 49.34 (+18.3%) |
| Earnings Date | May 10, 2022 |
About HALO
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcu...
Financial Performance
In 2021, HALO's revenue was $443.31 million, an increase of 65.67% compared to the previous year's $267.59 million. Earnings were $402.71 million, an increase of 211.97%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for HALO stock is "Buy." The 12-month stock price forecast is 49.34, which is an increase of 18.35% from the latest price.
News
Hart-Scott-Rodino Waiting Period Expires for Halozyme's Acquisition of Antares Pharma
SAN DIEGO , May 12, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, a...
Halozyme (HALO) Q1 Earnings Miss, Royalties Aid Y/Y Revenues
Halozyme (HALO) first-quarter earnings and sales miss estimates. Strong demand for the partnered drug, subcutaneous Darzalex, boosts the top line.
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -2.08% and 7.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Halozyme Reports First Quarter 2022 Results
First Quarter Revenue of $117.3 million, Representing a 32% YOY Increase, with GAAP Diluted Earnings per Share of $0.43 and Non-GAAP Diluted Earnings per Share of $0.47 Record Quarterly Royalties in the...
ANTARES PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequa...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Antares Pharma, In...
Halozyme To Host First Quarter 2022 Financial Results Webcast and Conference Call
SAN DIEGO , May 3, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2022 on May 10 at 4:30 p.m. ET / 1:30 p.m.
ANTARES PHARMA INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Antares Pharma, Inc. - ATRS
CEDARHURST, N.Y.--(BUSINESS WIRE)--Kuznicki Law PLLC is investigating the proposed sale of Antares Pharma, Inc. (NasdaqCM: ATRS) to Halozyme Therapeutics, Inc. (NasdaqGS: HALO). Under the terms of the p...
HALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMA
SAN DIEGO , April 26, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purc...
Halzoyme (HALO) Up 8.3% YTD: Will It Continue to Trend Higher?
Halozyme's (HALO) revenues are driven by strong demand for new partnered drugs. Restructuring initiatives are boosting margins.
Halozyme Open to More Acquisitions After Antares Deal
After inking a deal to acquire small-cap auto-injector specialist Antares Pharma Inc. ( ATRS , Financial) for about $960 million, San Diego-based Halozyme Therapeutics Inc. ( HALO , Financial) may not b...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Antares Pharma, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - April 18, 2022) - Rigrodsky Law, P.A. is investigating Antares Pharma, Inc. ("Antares") (NASDAQ: ATRS) regarding possible breaches of fiduciary duties and other v...
Halozyme (HALO) to Acquire Antares for Auto Injector Platform
Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.
SHAREHOLDER ALERT: Weiss Law Investigates Antares Pharma, Inc.
NEW YORK , April 13, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Antares Pharma, Inc. ("Antares" or the "...
Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity
Halozyme Therapeutics Inc (NASDAQ: HALO) will acquire Antares Pharma Inc (NASDAQ: ATRS) for $5.60 per share, valuing Antares at approximately $960 million. The transaction is expected to be accretive to...
Antares Pharma stock rockets after Halozyme buyout deal for a near-50% premium
Shares of Antares Pharma Inc. ATRS, -0.27% rocketed 46.3% in premarket trading Wednesday toward a two-decade high, after the specialty pharmaceutical company agreed to be acquired by Halozyme Therapeuti...
Halozyme to Acquire Antares Pharma to Create a Specialty Product and Drug Delivery Leader
Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business wit...
Halozyme's (HALO) ENHANZE Drives Sales Amid Rising Competition
Halozyme (HALO) is attracting partnerships from several large pharma companies as well as biotechs, courtesy of its ENHANZE technology. Royalties and product supply to partners are likely to drive reven...
Halozyme (HALO) Inks Collaboration Deal With Chugai Pharma
Halozyme (HALO) and Japan-based Chugai Pharma sign a collaboration agreement, which gives the latter an exclusive right to Halozyme's ENHANZE technology to develop a therapy for an undisclosed target.
Halozyme Therapeutics (HALO) Up 11.4% Since Last Earnings Report: Can It Continue?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® T...
SAN DIEGO , March 24, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global collaboration and license agreement with Chugai Pharmaceutical Co., Ltd. that gives exclusi...
Positive Topline Results Announced from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod Using ENHANZE® Drug Deliv...
- Study met primary endpoint, demonstrating noninferior total IgG reduction at day 29 with subcutaneously administered efgartigimod compared to intravenous (IV) administration - - Biologics License Appl...
Halozyme Appoints Moni Miyashita to Board of Directors
SAN DIEGO , March 15, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Moni Miyashita to its board of directors. Ms. Miyashita is an accomplished execut...
Halozyme (HALO) Q4 Earnings Top, Royalties Drive Revenues
Halozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022.
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS
SAN DIEGO, Feb. 22, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided an update ...